Art

J-GLOBAL ID：202202276346649083   Reference number：22A1740600

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

Majorの珍しいEGFR変化を有する進行非小細胞肺癌患者に対するダコミチニブ:中国における二重中心,単腕,両腕のコホート試験【JST・京大機械翻訳】

Author (12)： Li Hong-Shuai (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Yang Guang-Jian (2Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji’nan, China) ,  Cai Yi (3Independent Researcher, Ellicott City, MD, United States) ,  Li Jun-Ling (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Xu Hai-Yan (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Zhang Tao (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Zhou Li-Qiang (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Wang Yu-Ying (4Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China) ,  Wang Jin-Liang (4Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China) ,  Hu Xing-Sheng (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) ,  Yan Xiang (4Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China) ,  Wang Yan (1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)
Material： Frontiers in Pharmacology (Web)
Volume： 13  Page： 919652  Publication year： 2022 
JST Material Number： U7091A  ISSN： 1663-9812  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Objective: Dacomitinib has bee...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A1740600&from=J-GLOBAL&jstjournalNo=U7091A") }}

Thesaurus term： mutation ,  People's Republic of China ,  woman ,  *patient ,  percent conversion ,  dose ,  *population(statistics) ,  *non-small cell lung cancer ,  *EGF receptor ,  *cohort study ,  *advanced cancer
Semi thesaurus term： RECIST ,  無増悪生存期間 ,  *進行非小細胞肺癌 ,  全生存率 ,  有害事象 , 【Automatic Indexing@JST】

Author keywords (5)： dacomitinib ,  non-small cell lung cancer ,  major uncommon EGFR mutations ,  efficacy ,  safety

JST classification (1)： Tumors(=neoplasms)of respiratory system  (GI04000G)

Reference (33)：

• BaekJ. H., SunJ. M., MinY. J., ChoE. K., ChoB. C., KimJ. H., et al (2015). Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutated Non-small Cell Lung Cancer except Both Exon 19 Deletion and Exon 21 L858R: a Retrospective Analysis in Korea. Lung Cancer 87 (2), 148-154. doi: 10.1016/j.lungcan.2014.11.013
• BrindelA., AlthakfiW., BarritaultM., WatkinE., MauryJ. M., BringuierP. P., et al (2020). Uncommon EGFR Mutations in Lung Adenocarcinoma: Features and Response to Tyrosine Kinase Inhibitors. J. Thorac. Dis. 12 (9), 4643-4650. doi: 10.21037/jtd-19-3790
• ChengY., MokT. S., ZhouX., LuS., ZhouQ., ZhouJ., et al (2021). Safety and Efficacy of First-Line Dacomitinib in Asian Patients with EGFR Mutation-Positive Non-small Cell Lung Cancer: Results from a Randomized, Open-Label, Phase 3 Trial (ARCHER 1050). Lung Cancer 154, 176-185. doi: 10.1016/j.lungcan.2021.02.025
• ChiuC. H., YangC. T., ShihJ. Y., HuangM. S., SuW. C., LaiR. S., et al (2015). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J. Thorac. Oncol. 10 (5), 793-799. doi: 10.1097/JTO.0000000000000504
• ChiuC. H., YangC. T., ShihJ. Y., HuangM. S., SuW. C., LaiR. S., et al (2015). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J. Thorac. Oncol. 10 (5), 793-799. doi: 10.1097/JTO.0000000000000504

Terms in the title (7)： EGFR ,  進行非小細胞肺癌 ,  患者 ,  ダコミチニブ ,  中国 ,  腕 ,  コホート試験